Comment on: Development of psoriasis during treatment with dupilumab: A systematic review
- PMID: 34311044
- DOI: 10.1016/j.jaad.2021.06.893
Comment on: Development of psoriasis during treatment with dupilumab: A systematic review
Conflict of interest statement
Conflicts of interest Dr Damsky serves as a consultant for Pfizer, Eli Lilly, and TWi Biotechnology; has research funding from Pfizer; and receives licensing fees from EMD/Millipore/Sigma. Dr Cohen has no conflicts of interest to declare.
Comment on
-
Development of psoriasis during treatment with dupilumab: A systematic review.J Am Acad Dermatol. 2022 Mar;86(3):708-709. doi: 10.1016/j.jaad.2021.05.013. Epub 2021 May 19. J Am Acad Dermatol. 2022. PMID: 34022319 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
